Skip to main navigation
  • About
    • Overview
    • Mission & Vision
    • Operating Principles
    • Management
    • Board of Directors
  • Science
    • Overview
    • Therapeutic Areas
    • Therapeutic Platforms
    • Technology Platforms
    • Publications
  • Pipeline
    • Overview
    • Precigen Pipeline
  • Subsidiaries
    • Overview
    • Precigen Actobio
    • Precigen Exemplar
    • Precigen Triple-Gene
  • Careers
    • Overview
    • Job Postings
    • Postdoc Program
    • Benefits
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock
    • Financials
    • Governance
    • Resources
  • Contact
    • Contact
    • Locations
  • About
    • Overview
    • Mission & Vision
    • Operating Principles
    • Management
    • Board of Directors
  • Science
    • Overview
    • Therapeutic Areas
    • Therapeutic Platforms
    • Technology Platforms
    • Publications
  • Pipeline
    • Overview
    • Precigen Pipeline
  • Subsidiaries
    • Overview
    • Precigen Actobio
    • Precigen Exemplar
    • Precigen Triple-Gene
  • Careers
    • Overview
    • Job Postings
    • Postdoc Program
    • Benefits
  • Investors
    • Overview
    • Press Releases
    • Events
    • Stock
    • Financials
    • Governance
    • Resources
  • Contact
    • Contact
    • Locations
PRECIGEN Investors

Press Releases

IR Nav

  • Press Releases
  • Events & Presentations
  • Stock
  • Financials
  • Governance
  • Resources

Press Releases

Jan 22, 2021
Precigen Announces Pricing of $112.5 Million Public Offering of Common Stock
Learn More
Jan 21, 2021
Precigen Announces Proposed Public Offering of Common Stock
Learn More
Jan 13, 2021
Precigen Provides Pipeline Updates at the 39th Annual J.P. Morgan Healthcare Conference
Learn More
Jan 06, 2021
Precigen to Present at the 39th Annual J.P. Morgan Healthcare Conference
Learn More
Jan 05, 2021
Precigen Announces Clearance of IND to Initiate Phase I Study of PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP)
Learn More

Upcoming Events

More events are coming soon.

Media Kit

Precigen maintains a media kit with our corporate logo and our CEO’s headshot and bio that can be used by media for editorial purposes. Should you have any questions or seek assets not included in our media kit, please contact:

press@precigen.com

Download
Media Kit
Download
Advancing Medicine with precision™
  • About
    • Overview
    • Mission & Vision
    • Operating Principles
    • Management
    • Board of Directors
  • Science
    • Overview
    • Therapeutic Areas
    • Therapeutic Platforms
    • Technology Platforms
    • Publications
  • Pipeline
    • Overview
    • Precigen Pipeline
  • Subsidiaries
    • Overview
    • Precigen Actobio
    • Precigen Exemplar
    • Precigen Triple-Gene
  • Careers
    • Overview
    • Job Postings
    • Postdoc Program
    • Benefits
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock
    • Financials
    • Governance
    • Resources
  • Contact
    • Contact
    • Locations

Headquarters

Precigen, Inc.
20358 Seneca Meadows Parkway
Germantown, MD 20876

Connect

  • linkedin
  • twitter

Privacy and Legal Menu

  • Privacy Policy
  • Legal Notices

Copyright

© Precigen. All Rights Reserved.